News Joe Jensen 11/10/22 Joe Jensen 11/10/22 CH Innovations and Catalytic Impact Foundation invest in DeckTherapeutics Read More Joe Jensen 9/20/22 Joe Jensen 9/20/22 DeckTherapeutics appoints Professor Yechezkel Barenholz, PhD to its Board of Directors Read More Joe Jensen 9/13/22 Joe Jensen 9/13/22 DeckTherapeutics appoints Dr. Larry Gold to the Board of Directors Read More Joe Jensen 9/5/22 Joe Jensen 9/5/22 DeckTherapeutics’ technology platform featured in The Wall Street Journal Read More Joe Jensen 7/8/22 Joe Jensen 7/8/22 DeckTherapeutics awarded research grant for studies of THDG3 in higher animals Read More Joe Jensen 10/21/21 Joe Jensen 10/21/21 Dr. Rebecca Juliano joins DeckTherapeutics as Clinical Advisor Read More Joe Jensen 8/3/21 Joe Jensen 8/3/21 DeckTherapeutics announces grant of patent Read More Joe Jensen 1/7/21 Joe Jensen 1/7/21 DeckTherapeutics announces the formation of Scientific Advisory Board Read More Joe Jensen 1/1/21 Joe Jensen 1/1/21 DeckTherapeutics participates in Biotech Showcase Read More Joe Jensen 12/11/20 Joe Jensen 12/11/20 DeckTherapeutics appoints new CEO Read More Joe Jensen 12/1/20 Joe Jensen 12/1/20 DeckTherapeutics obtains exclusive license to omega-3 IPR from DSM Nutrition Read More Joe Jensen 3/30/20 Joe Jensen 3/30/20 DeckTherapeutics obtains exclusive license to omega-3 IPR from the United States Army Read More
Joe Jensen 11/10/22 Joe Jensen 11/10/22 CH Innovations and Catalytic Impact Foundation invest in DeckTherapeutics Read More
Joe Jensen 9/20/22 Joe Jensen 9/20/22 DeckTherapeutics appoints Professor Yechezkel Barenholz, PhD to its Board of Directors Read More
Joe Jensen 9/13/22 Joe Jensen 9/13/22 DeckTherapeutics appoints Dr. Larry Gold to the Board of Directors Read More
Joe Jensen 9/5/22 Joe Jensen 9/5/22 DeckTherapeutics’ technology platform featured in The Wall Street Journal Read More
Joe Jensen 7/8/22 Joe Jensen 7/8/22 DeckTherapeutics awarded research grant for studies of THDG3 in higher animals Read More
Joe Jensen 10/21/21 Joe Jensen 10/21/21 Dr. Rebecca Juliano joins DeckTherapeutics as Clinical Advisor Read More
Joe Jensen 1/7/21 Joe Jensen 1/7/21 DeckTherapeutics announces the formation of Scientific Advisory Board Read More
Joe Jensen 12/1/20 Joe Jensen 12/1/20 DeckTherapeutics obtains exclusive license to omega-3 IPR from DSM Nutrition Read More
Joe Jensen 3/30/20 Joe Jensen 3/30/20 DeckTherapeutics obtains exclusive license to omega-3 IPR from the United States Army Read More
